Top News

Aug 13, 2018
By BioPharm International Editors
The new drug, Onpattro (patisiran), by Alnylam Pharmaceuticals, is in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.
Aug 09, 2018
By BioPharm International Editors
The European Medicines Agency (EMA) will temporarily scale back activities as it copes with “significant staff loss” and prepares for the next phase in its continuity plan.
Jul 19, 2018
In launching FDA’s Biosimilar Action Plan, Gottlieb takes innovator companies to task for delaying competitive biosimilar products.
Jul 19, 2018
By BioPharm International Editors
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
Jul 12, 2018
By BioPharm International Editors
The agency is releasing six new draft guidances to provide a regulatory framework for handling gene therapies.
Jul 11, 2018
By BioPharm International Editors
Pfizer creates separate business units for innovator medicines, generic drugs, and consumer products.
Jul 11, 2018
By BioPharm International Editors
The company has received clearance from the United States Federal Trade Commission for the proposed acquisition of Shire, a deal valued at $62 billion.
Jul 03, 2018
By BioPharm International Editors
The pharma major intends to spinoff Alcon as a stand-alone eye-care devices company.
Jul 03, 2018
By BioPharm International Editors
Biogen will pay Samsung BioLogics approximately $700 million to increase its stake in Samsung Bioepis to approximately 49.9%.
Jun 26, 2018
By BioPharm International Editors
Strategic restructuring is designed to position GE Healthcare as a pure-play healthcare company.
native1_300x100
lorem ipsum